TMPRSS2 and COVID-19: For example, our finding that SARS-CoV-2 infects CMs via an endolysosomal route may indicate that clinical trials which target TMPRSS2 to prevent COVID-19 (55, 56) may not afford effective cardioprotection without orthogonal targeting of endosomal proteases (57).